International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 468-472 , May 2010

Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study

  • Pavlos Myrianthefs

      Affiliations

    • Intensive Care Unit, ‘KAT’ Hospital, School of Nursing, Athens University, Athens, Greece
    • ,
  • Sophia L. Markantonis

      Affiliations

    • Athens University, Faculty of Pharmacy, Laboratory of Biopharmaceutics and Pharmacokinetics, Athens 157.71, Greece
    • Corresponding Author InformationCorresponding author. Present address: Faculty of Pharmacy, Department of Pharmaceutical Technology, Laboratory of Biopharmaceutics and Pharmacokinetics, University of Athens, Panepistimiopolis, Athens 157.71, Greece. Tel.: +30 210 727 4676; fax: +30 210 727 4027.
    • ,
  • Penelope Evaggelopoulou

      Affiliations

    • Intensive Care Unit, ‘KAT’ Hospital, School of Nursing, Athens University, Athens, Greece
    • ,
  • Stratos Despotelis

      Affiliations

    • Athens University, Faculty of Pharmacy, Laboratory of Biopharmaceutics and Pharmacokinetics, Athens 157.71, Greece
    • ,
  • Effimia Evodia

      Affiliations

    • Intensive Care Unit, ‘KAT’ Hospital, School of Nursing, Athens University, Athens, Greece
    • ,
  • Dimitris Panidis

      Affiliations

    • Athens University, Faculty of Pharmacy, Laboratory of Biopharmaceutics and Pharmacokinetics, Athens 157.71, Greece
    • ,
  • George Baltopoulos

      Affiliations

    • Intensive Care Unit, ‘KAT’ Hospital, School of Nursing, Athens University, Athens, Greece

Received 25 November 2009 ,Accepted 23 December 2009.

References 

  1. Blot S, Dimopoulos G, Rello J, Vogelaers D. Is Candida really a threat in the ICU?. Curr Opin Crit Care. 2008;14:600–604
  2. Rüping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs. 2008;68:1941–1962
  3. FDA Antiviral Drugs Advisory Committee. Briefing document for voriconazole (oral and intravenous formulations). FDA Antiviral Drugs Advisory Committee; 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf [accessed 20 January 2010].
  4. Tomaszewski K, Purkins L. The pharmacokinetics and safety of sulphobutylether-β-cyclodextrin (SBECD). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 16–19 December 2001, Chicago, IL. ASM Press: Washington, DC; 2001;[Abstract 23]
  5. Von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol. 2006;6:6
  6. US Food and Drug Administration. Background document for the Antiviral Drug Products Advisory Committee meeting. FDA; 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_02_FDA-voriconazole.htm [accessed 20 January 2010].
  7. Abel S, Allan R, Gandelman K, Tomaszewski K, Webb DJ, Wood ND. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Invest. 2008;28:409–420
  8. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21:580–586
  9. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46:235–243
  10. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201–211
  11. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis. 2004;39:1241–1244
  12. Alvarez-Lerma F, Allepuz-Palau A, Garcia MP, Angeles Leon M, Navarro A, Sanchez-Ruiz H, et al. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function. J Chemother. 2008;20:93–100
  13. Gage R, Stopher DA. A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal. 1998;17:1449–1453
  14. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109:1532–1535
  15. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630–637
  16. Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43(Suppl. 1):S28–S39
  17. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31:540–547
  18. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166–2172
  19. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570–1572
  20. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563–571
  21. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006;136:739–742
  22. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005;35:509–513
  23. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46:2546–2553
  24. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47:3165–3169
  25. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol. 2006;44:819–826
  26. Mohammedi I, Piens MA, Padoin C, Robert D. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients. Eur J Clin Microbiol Infect Dis. 2005;24:358–360
  27. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45:649–663

PII: S0924-8579(10)00024-5

doi: 10.1016/j.ijantimicag.2009.12.021

International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 468-472 , May 2010

Article Tools